Allergan PLC (AGN)

NYSE
193.02
0.00(0.00%)
  • Volume:
    0
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    191.64 - 193.38

AGN Overview

Prev. Close
192.99
Day's Range
191.64-193.38
Revenue
16.1B
Open
193.01
52 wk Range
0-0
EPS
-7.59
Volume
0
Market Cap
63.65B
Dividend (Yield)
2.96
(1.53%)
Average Vol. (3m)
3,077,701
P/E Ratio
-
Beta
1.2
1-Year Change
0%
Shares Outstanding
329,805,791
Next Earnings Date
-
What is your sentiment on Allergan PLC?
or
Market is currently closed. Voting is open during market hours.

Allergan PLC Company Profile

Employees
17400

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, central nervous system, women’s health, and anti-infective therapeutic products. The company also offers breast implants and tissue expanders; In addition, it develops medical and cosmetic treatments; treatments for neurodegenerative disorders; and inflammatory and fibrotic diseases. It has a collaboration, option, and license agreement with Lyndra, Inc. to develop orally administered products for the treatment of Alzheimer’s disease; strategic alliance and option agreement with Editas Medicine, Inc.; and Allergan plc also has licensing agreements with Assembly Biosciences, Inc. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was incorporated in 2013 and is headquartered in Dublin, Ireland. As of May 8, 2020, Allergan plc operates as a subsidiary of AbbVie Inc.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
Technical IndicatorsStrong BuyStrong BuySellStrong BuyStrong Buy
SummaryStrong BuyStrong BuyNeutralStrong BuyStrong Buy
  • I have been watching this since before the merger news broke. and the way it has been acting and the large "dark pool" orders and the fat fingers down its acting the same way...there will be more news soon. idk what it may be another company with a bigger offer or something...I know theyll probably beat eps. and they have declared a .74 cent dividend . they also have new drugs available in the US and new trials starting . would not be surprised to see another buyout off of 200 ps or even higher.
    2
    • I would be very surprised if another buyout offer came in. As for anti-trust issues, I don't see that either. No overlapping drugs. The Democrats that want to block the merger, just dislike pharma company's and this merger is a way for some of the presidential candidates to get some airtime and try to convince Ameticans this merger is a way for bug pharma to get more leverage, when all it really is, is a cost savings initiative to combine and eliminate some duplication.
      0
  • news will come soon of a potential better offer. price is acting same as it was before...just wait ...
    1
    • Really, really odd that this is down. There must be doubts about this going through.
      0
      • Shooting to 188$
        1
        • Not sure another bidder will come to the table. If PFE hadn't just paid cash for ARRY, they might have come to the party here.
          0
        • oh yea put some more of my out of the money call options $30 in the money!!!
          1
      • AGN $164.00 +26.57%
        0
        • 170$
          0
          • Actually will get to 188 since that is the selling price. not sure why you're hung on 170.
            0
          • John Perry The deal is not for sure! It is scheduled for early 2020. So many of these deals do not happen. You should read the buyout more carefully. It states a 120 per share with a .81 ABBV per share add. .81 * ABBV current price per share 67.8 = 174.91. That is your best case scenario. What happens when ABBV drops to $50 before the deal. Now your looking at $160 a share.
            0
        • Triangle?
          0
          • Law suits are coming on their breast implants that have caused cancer
            1
            • Potential buyout candidate. But probably not worth the downside risk.
              0
              • $143
                0
                • 140.16
                  0
                  • let it fly back...
                    0
                    • Sheesh.! About time the rally started.  This should be in the 220's.
                      0
                      • clouds o lot of clouds
                        0
                        • This sell off seems overdone at this point.
                          0
                          • what do u think about allergan?
                            0
                            • Stock is in a downtrend, next support or target price is 133.
                              0
                          • Any rumor about imnp and allergan..?
                            0
                            • Buy pharma in bet for trump new medical system
                              0
                              • Can someone advise about the allergan situation , what to do hold or sell ?
                                0
                                • Hold bro. Do not sell.. they want them cheap. Teva deal at the end of this month..
                                  0
                                • I agree !
                                  0
                              • is it a good time to buy Allergan now ?
                                0
                                • I think it is .... 190 strong support
                                  0
                              • Thxfor the opportunity to buy it 25% lower in order to win free 30%
                                0
                                • My next add $250
                                  0
                                  • allergen is also a good stock however beware of the stock price choose pfizer if you cant afford it
                                    0
                                    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.